

RESPONSE

I. Status of the Claims

Claims 1-7 are presently pending. No prior art rejections are presently of record. For the convenience of the Examiner, a clean copy of the pending claims is attached hereto as Exhibit A.

II. The Present Claims Are Patentable And The Rejections of Record Should Be Withdrawn.

a) Rejections Under 35 U.S.C. § 101

The Examiner's rejections of Claims 1-7 under 35 U.S.C. section 101 is respectfully traversed. The Examiner has apparently adopted the position that the claimed invention lacks patentable utility due to its not being supported by either a specific and/or substantial utility or a well established utility.

As discussed above, the human genome has been sequenced and subsequent analysis has verified that only a minor fraction of the genome encodes exon sequence that can be spliced, polyadenylated, and used to produce corresponding proteins. From a pharmaceutical development perspective the critical question remains determining which proteins present meaningful opportunities for the development of pharmaceutical products?

The Examiner is respectfully requested to consider that the specifically described novel mutated ES cell clones are each *specifically* identified by corresponding exon sequences (presented in the Sequence Listing) that provide *a unique (and hence, highly specific) resource* for mapping that portion of the murine genome that encodes the described exon sequence and, by proxy, that portion of the human genome that encodes the human ortholog of the described sequences. More importantly, the specification teaches that genetically engineered mutation present in the specifically described mouse ES cell clone is designed to disrupt the normal function of the mutated allele. The specification also teaches that the otherwise totipotent ES cells can be used to generate animals that specifically lack the function of the disrupted gene. These animals provide a novel resource for specifically determining the physiological role of the mutated gene. In this

instance, the gene that was disrupted by the ES cell clone that encodes the transcript corresponding to SEQ ID NO:393 normally encodes the neurexin II protein (see GENPEPT accession no. 205715 as shown in Figure 2 of the specification— accordingly, there can be no question that those skilled in the art at the time the invention was filed would have known that SEQ ID NO:393 corresponded to a ES cell clone mutating the neurexin II gene). Genetically engineered mice made using the methods referenced in the specification using ES cell clones having mutations in the murine ortholog of the neurexin II gene displayed enhanced sensorimotor gating/attention in conjunction with reduced coordination (optic disc abnormalities were also noted). Accordingly, by using the specifically described mutated ES cells and following the teaching in the specification, employees of the Assignee of the present application were able to first determine the role of the neurexin II gene in the broader context of mammalian physiology. More importantly, the above data indicate that the neurexin II protein is an overt target for the development of neurological agents. This is precisely the type of demonstrated pharmaceutical utility contemplated by U.S. patent law, and represents the type of specific and substantial and well-established utility that even satisfies the substantially more onerous U.S. Patent office utility guidelines. Given that there can be no question that the “final product” of the claimed invention has already been used to identify a substantial pharmaceutical utility, there can be no question that the presently described mouse ES cell line also has a substantial, credible, and well established utility. In brief, the present invention has shown that the neurexin II protein is one of the relatively small number of proteins that have been shown to have pharmaceutical relevance. In view of this fact, there can be no question that the claimed ES cell line has a credible, substantial, and specific “real world” utility. Accordingly, the Examiner is respectfully requested to withdraw the pending rejection of the claims under 35 U.S.C. §101.

From a broader policy perspective, the Examiner is also requested to consider that public and private efforts have spent several billion dollars to obtain human genomic sequence data (and that corporate partners have committed to spending millions of dollars for early access to human genomic sequence), one can state that such genomic sequence data, in part or in whole, have a demonstrated, substantial, and specific utility fully within that contemplated by 35 U.S.C. section 101 (see also the issues of “Nature” (2001, 409:745-964) and “Science” (2001, 291:1304-1351 that were both dedicated Human genomic sequence data). The practical implementation of the

present invention adds value to human genomic data by assigning critical functional annotation to the human sequence data. It is thus axiomatic that an invention that adds value to an asset having *demonstrated and substantial economic and scientific utility* must also have substantial utility. As such, it should be clear that even in the broader context of the application as a whole (as opposed to the specifically claimed ES cell line), the presently described invention has a demonstrated substantial utility. Moreover, each of the specifically described mouse ES cell clones provide a *specific* resource for discovering the *in vivo* function of a *specific* human ortholog. When these ES cells were used as described in the specification to generate knockout animals capable of germ line transmission of the engineered allele, the medical potential of the neurexin II product (as a target for antagonism by a drug) was discovered. Accordingly there can be no doubt about the specific utility of the presently claimed invention.

To the extent that the Examiner may question the broader utility of knockout animals, Applicants request that the Examiner consider that the broader scientific community has already acknowledged and accepted the value of knockout mice for discovering the function of genomic sequence information. As conclusive evidence of such, the Applicants' respectfully direct the Examiner's attention to the recent announcement of the winners of the 2001 Lasker awards. Reproduced below for the Examiner's convenience are the comments by Lasker award presenter Ira Herskowitz:

Albert Lasker Award for Basic Medical Research, 2001
Comments at the Awards ceremony
Presented by Ira Herskowitz

"The release of the human genome sequence in draft form makes this a landmark year in the history of biology. Now we know that we have 30,000 or so genes (or is it 50,000?). We are now faced with several important questions, which include:

First, what are the functions of these genes and the proteins that they code for? And, second, how can we use this information to improve human health?

Until the ability to knock out genes in the mouse was developed, determining the function of human genes seemed largely out of reach, tantalizingly so. For example, we might know of a human protein that is found only in certain cells of the brain and suspect what it might do, but how can we find out? Or, we might know of a gene in the fruitfly that is necessary for its development and see that humans have a very similar gene. Does it perform a similar function in humans? A powerful way to link a gene to function is to study the behavior of a

mutant that lacks that gene and then see what the mutant can and cannot do. It's somewhat like disabling an automobile by removing one part and then inferring the function of the part that was removed. But we can't knock out genes in a human, so how can such mutants be produced?

The mighty mouse has come to the rescue. Its genes are typically 95% identical in sequence to ours, and we share the vast majority of our genes with the mouse. Despite the obvious differences between human and mouse in morphology and in some physiological processes, these differences are greatly outweighed by our similarities: they have kidneys and brains like ours; they have an immune system and develop a lot like humans; and they get diseases such as cancer and others that affect their cardiovascular and nervous systems like us. In some respects, mice are "pocket-sized humans". The bottom line is that the mouse provides the opportunity, dreamed about for decades, to make the link between a mammalian gene and its function. How is this done?

Building on more than one hundred years of genetic and embryological studies of the mouse, **Mario Capecchi**, **Martin Evans**, and **Oliver Smithies** have created a magic wand by which it is possible to modify any mouse gene with exquisite precision -- to completely delete it or to produce a specifically altered form of the gene.

The same technology also makes it possible to go the other direction - instead of knocking out a mouse gene, it's possible to restore function to a gene that is defective.

Let's now look at the process by which a mouse knockout is constructed.

A key piece of starting material is a mouse gene that's already been cloned: it might be a mouse gene corresponding to a human gene or a mouse gene corresponding to a fruitfly or nematode gene. The goal is to construct a mouse that lacks this gene. The second key piece of starting material is a special mouse cell line where the gene is going to be knocked out.

There are three steps for constructing a mouse knockout. In the first, a cloned gene is manipulated in a test tube to delete all or part of the gene. This is routine molecular biology. In step two, the mutated DNA is introduced into special mouse cells, where the mutated DNA replaces a normal gene copy in the chromosome. The crucial aspect of this process is that the mutant gene has to find the related sequences in the chromosome, so-called homologous DNA sequences, and then undergo recombination to switch places with the good gene. The ability of the introduced DNA to find the homologous DNA sequences is called "gene targeting". There was no evidence for gene targeting in animal cells growing in culture and great doubt about whether this could be done. This is where Capecchi and Smithies made their most important contributions. In the third step, the cells with the targeted, inactivated gene are grown into a mouse that has this inactivated gene. It was Martin Evans who isolated the cell lines that made this possible and showed that genetic changes introduced into these cells in culture could be transmitted through the germ line and into mutant, progeny mice.

Let's now look at our awardees.

Verona, Italy has given us not only Romeo and Juliet, but Mario Capecchi. His early days as a child included living in orphanages and on the street in war-torn Italy from 4-9 years of age, then growing up in a nurturing Quaker environment in Pennsylvania. I refer interested people to articles that are available on the Internet. Capecchi did his graduate work at Harvard with Jim Watson and was enormously productive, making textbook discoveries on molecular mechanisms underlying protein synthesis. This was a golden age of molecular biology. Mario learned his lessons well, and when he established his own laboratory at the University of Utah in 1973, he sought to bring molecular genetics to animal cells growing in culture and learn how to manipulate the genes of these cells. This led him to undertake a series of studies beginning in 1977 that demonstrated gene targeting in animal cells and culminated in the construction of one of the first knockout mice in 1989. His first indications of homologous recombination in animal cells were published in 1982 and fueled a series of logical and remarkable studies that provide the standard methods for knocking out mouse genes.

Oliver Smithies was trained as a biochemist, but throughout his scientific career, homologous recombination kept on cropping up, and he came to think about how it could be used to fix defective genes. Smithies was born in Halifax, England and raised in the United Kingdom. After studying at Oxford University, he came to the University of Wisconsin for postdoctoral studies in 1951 and was on the faculty there for 28 years, from 1960-1988. He is presently at the University of North Carolina at Chapel Hill, and may well have flown here in his own little plane to attend this luncheon. After important early contributions springing from his development of a method for fractionating proteins, he became intrigued by the structure and evolution of mammalian genes, which meant that he became involved in cloning these genes.

In the early 1980s, Smithies began to wonder whether homologous recombination - gene targeting - could be carried out experimentally to correct a defective gene, for example, a mutant globin gene. For this type of genetic correction to occur, exogenously introduced DNA would have to target to the homologous chromosomal DNA sequence and recombine with it. But was this possible? No one had demonstrated gene targeting in animal cells.

In 1985 Smithies and colleagues demonstrated that they could introduce a DNA segment containing part of the globin gene into cells and then find cells in which this DNA segment had targeted to the chromosomal globin gene. This was a tour-de-force of sophisticated molecular genetics. His strategy was completely different from that used by Capecchi and though laborious, the demonstration of targeting was unequivocal.

These studies from the Capecchi and Smithies laboratories provided one of the essential ingredients for constructing gene knockouts in mice, the ability to target genes in cultured animal cells. The crucial next step was to take mouse cell lines modified in this manner and produce mice from them.

The history of mammalian embryology is intellectually rich and filled with great practical applications. It was nurtured by the agricultural industry among others and involved important work with rabbits and mice. The UK can lay claim to many important contributions in this area, and thus Martin Evans is part of a distinguished tradition. Evans was born in the UK and graduated from Cambridge in 1963. He then went to University College London, where he studied vertebrate development using frogs. After working with a certain type of cancer cell line that could differentiate in cell culture and be used to generate whole mice, Evans set out to isolate normal cells from an early mouse embryo that would have similar properties. Work from Richard Gardner argued for the existence of such cells, but culturing them had been elusive. In 1981, Martin Evans and Matt Kaufman and, independently, Gail Martin, in the U.S. were successful in isolating such cells, which have become known as embryonic stem cells, "ES cells". Evans then carried out an important series of experiments with his students Allan Bradley and Elizabeth Robertson that demonstrated that these ES cells could contribute to the mouse germ line. They further showed that genetically manipulated ES cells could transfer their genetic changes to progeny mice. The importance of ES cells was immediately recognized by Capecchi and Smithies, who learned how to grow ES cells and demonstrated that they could carry out targeted genetic alterations with them.

The first knockout mice constructed by gene targeting were published in 1989, and the rest is history. More than 4,000 different knockout mice have been constructed in the last dozen years, and many more are in the works! To keep on top of this fast-moving field, I suggest looking at the Jackson Laboratory's website, where you can find columns called "It's a Knockout!" and "KO of the Month".

The ability to modify the genetic make-up of a mouse by design provides a wealth of information on the function of the gene that is knocked out. Every aspect of mammalian physiology is being penetratingly analyzed by this technique. Particularly notable are the discoveries made on how the immune system functions, which have enormous implications for human health. Knockout mice made it possible to demonstrate unequivocally the molecular basis for prion diseases such as mad-cow disease. Knockout technology is also used to create mice that have versions of human diseases such as cystic fibrosis, muscular dystrophy, atherosclerosis, and many others. These mice make it possible to follow the course of a disease and provide an opportunity to identify and test drugs to ameliorate or cure these diseases.

The ability to precisely tailor mouse genes has completely revolutionized the practice of biomedical science for the last decade and is likely to become even more important in the decades to come. We are certain to reap an enormous bounty of information from knockout mice and reap great benefits for the improvement of human health."

In view of the above remarks, there should be no doubt that the mutated ES cell clones of the present invention have utility that the scientific community at large finds both well established and

credible. For a technical point of reference, the technology used to generate the presently described mutated clones has, in just a few years, produced and identified many fold more identified and characterized ES cells clones than have cumulatively been produced to date *by the world-wide scientific community* using the technologies that were the subject of the 2001 Lasker award referenced above.

In the event that the Examiner may still have some lingering doubts, Applicants invite the Examiner to further consider the guidance of the National Institute of Health which issued a request for applications entitled TOOLS FOR INSERTIONAL MUTAGENESIS IN THE MOUSE on January 25, 2001 (RFA-DA-01-011 which stated in part:

“This RFA solicits proposals for development of tools and techniques for the establishment of random and targeted sequence-tagged insertion libraries of embryonic stem (ES) cells that can be used to generate mutant mice in which the expression of the tagged gene could be controlled temporally and spatially. The development of such a resource for wide distribution to the scientific community would make it possible to scan the sequence database for any gene of interest and order the corresponding targeted ES cell line. Ideally, the insertional mutagenesis system developed would permit a wide range of genetic analyses and manipulations, including enhancer-trapping, conditional knockouts, conditional expression or overexpression, etc. It also would permit the larger community of investigators to utilize genomic resources efficiently. This effort complements ongoing National Institutes of Health (NIH) efforts to create and characterize induced point mutations in mice using ethylnitrosourea (ENU) and provides a functional genomics tool to translate the information from the Mouse Genome Sequencing Project. Further information about NIH initiatives on mouse genomics and genetics resources is available at <http://www.nih.gov/science/mouse>.”

Related to the above RFA, the Examiner is respectfully invited to visit the website www.baygenomics.ucsf.edu which describes a publicly funded gene trapping effort that further supports Applicants' position that the presently described invention has a well-established utility. As a point of technical comparison, the present application alone describes over 200 different ES cell clones that were generated using a technology that produced more identified ES cell clones in a month than the publicly funded BayGenomics effort has produced in a given year.

In brief, that branch of the U.S. government that is specifically tasked with sponsoring technologies having high biomedical utility, has already financially “validated” the utility of a related, albeit technically inferior, gene trap technology by providing many millions of dollars of funding for

such efforts. In view of the direct governmental validation of biomedical utility of gene trapped mouse ES cell clones, one cannot credibly assert that the presently described ES cell clones somehow lack a well-established utility.

In view of the overwhelming evidence of the substantial, credible, specific, and well-established utility of the presently claimed invention, the Applicants' respectfully request that the Examiner withdraw the pending rejection of Claims 1-7 under 35 U.S.C. section 101.

b) Rejections under 35 U.S.C. Section 112

The Examiner has also rejected Claims 1-7 under 35 U.S.C. section 112, first paragraph because those skilled in the art would allegedly not know how to use an invention lacking a bona fide utility. Given the fact that the Applicants have used the general and well established methods described in the specification to demonstrate that the "final product" of the claimed invention indeed has a real world pharmaceutical utility, the Examiner cannot credibly argue that those skilled in the art would not know how to use these well established and general techniques to "use" the claimed invention. As such, the Examiner is respectfully requested to withdraw this aspect of the rejection under 35 U.S.C. section 112, first paragraph.

The Examiner has rejected Claims 1-7 under 35 U.S.C. section 112, second paragraph for allegedly being indefinite over the recitation "wherein said gene is identifiable as corresponding to SEQ ID NO:393." The Examiner's rejection is respectfully traversed. Applicants contend that those skilled in the art would clearly understand that the specifically described genetically engineered ES cell clones represent the first clonally derived cells that have been engineered to disrupt the normal expression of the neurexin II gene. Those skilled in the art would also clearly understand that SEQ ID NO:393 represents exon sequence that is naturally encoded and expressed by the neurexin II locus. Given such understanding, there can be little question that one skilled in the art, a Ph.D. level scientist with several years of relevant experience, would have little difficulty readily understanding that the neurexin II gene corresponds to SEQ ID NO:393. Accordingly, the Examiner is respectfully requested to withdraw the pending rejection.

The Examiner has also rejected Claims 4-6 as allegedly indefinite over the recitation "wherein said polynucleotide sequence is present on a viral vector" because Claim 1 requires that

the polynucleotide sequence be inserted into the chromosome of the cell. The Examiner's rejection is respectfully traversed. Applicants contend that those skilled in the art at the time the present application was filed would clearly understand that genetically engineered mutagenic polynucleotides can be inserted into the host chromosome by a variety of means such as by homologous recombination (a.k.a. gene targeting), illegitimate recombination, or random integration of "naked DNA." Another means of introducing recombinant mutagenic polynucleotides into the host chromosome involves incorporating the mutagenic polynucleotides into a viral genome that in turn integrates into the host chromosome where it resides as proviral DNA (e.g., a retroviral gene trapping vector, etc.). Accordingly, those skilled in the art would clearly understand the meaning of the additional limitation that the recombinantly manipulated polynucleotide of Claim 1 be present within a viral vector. As such, the Examiner is respectfully requested to withdraw the pending rejection.

Claim 7 stands as rejected as allegedly indefinite over the use of the word "encode" to refer to non-amino acid sequence. The Examiner's rejection is respectfully traversed. Applicants note that a variety of scientific reviews have recently concluded that less than the five percent of the genome actually encodes exon sequence. That naturally begs the question of what the remainder of the genome encodes? What do the ribosomal RNA or tRNA genes "encode?" What portion of the genome "encodes" promoter or regulatory sequences? What percent of the genome "encodes" intron sequence? As is hopefully clear (and as a quick perusal of the web will bear out), those skilled in the art routinely use the word "encode" within a context that transcends the narrow meaning adopted by the Examiner in Paper No. 14. In any event, those skilled in the art would have little doubt that SEQ ID NO:393 represents spliced exon sequence. Given that it is well established that genomic DNA "encodes" exons (the Examiner is invited to query the web with the search term "encode exon" for rapid verification of Applicants' point), there can be little question that those skilled in the art would clearly understand what is meant by Claim 7's recitation of cell mutated in the gene that "encodes" (exon sequence present in) SEQ ID NO:393. Accordingly, the Examiner is respectfully requested to withdraw the pending rejection of Claim 7.

To the extent that the Examiner might suggest alternative claims language that would avoid any of the above amendments, the Examiner is invited to suggest such language if it will put the claim or claims in condition for allowance.


III. CONCLUSION

In view of the foregoing amendments and remarks, the Applicants believe that the application is in good and proper condition for allowance. Early notification to that effect is earnestly solicited.

If the Examiner feels that a telephone call would expedite the consideration of the application, the Examiner is invited to call the undersigned attorney at (281) 863-3333. The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-0892 for any matter in connection with this response, including fees for any extension of time, which may be required.

Respectfully submitted,

September 8, 2003
Date



Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3333

Customer # 24231

Exhibit A

Clean Version of The Pending Claims in U.S. Patent Application Ser. No. 09/750,456

1. (Previously Amended) A genetically engineered mammalian cell that has been mutated by a process comprising the insertion of a recombinantly manipulated polynucleotide sequence into a gene in said genetically engineered mammalian cell wherein said gene is identifiable as corresponding to at least one of SEQ ID NO: 393.
2. (Previously Presented) The genetically engineered mammalian cell of Claim 1, wherein said cell is murine.
3. (Previously Presented) A cell according to Claim 2, wherein said cell is an embryonic stem cell.
4. (Previously Presented) The genetically engineered mammalian cell of Claim 1, wherein said polynucleotide sequence is present on a viral vector.
5. (Previously Presented) A cell according to Claim 4, wherein said viral vector is a retroviral vector.
6. (Previously Presented) A cell according to Claim 4, wherein said viral vector additionally comprises regions of targeting DNA that facilitate gene targeting by homologous recombination.
7. (Previously Amended) An isolated murine embryonic stem cell line comprising an engineered retroviral gene trap vector in at least one gene comprising a polynucleotide sequence identifiable as corresponding to any one of SEQ ID NO: 393.